Here's what we'll cover
Here's what we'll cover
You may have heard there was a plan in the works. A Medicare pilot program that would have required insurers to cover affordable GLP-1 weight loss medications for seniors. It sounded promising.
It's gone now.
The Trump administration has dropped that plan, leaving millions of Medicare beneficiaries in the same place they've been for years — largely on their own when it comes to paying for semaglutide or tirzepatide.
Here's what actually happened, why it matters, and what you can realistically do if you're a senior trying to access these medications.
What Was the Medicare GLP-1 Pilot Program?
The pilot program was a Biden-era proposal designed to test whether Medicare could cover GLP-1 receptor agonists — drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) — specifically for obesity treatment in older adults.
Under current law, Medicare is prohibited from covering weight loss drugs. It can cover GLP-1s for type 2 diabetes or cardiovascular risk reduction, but not for obesity alone. The pilot was meant to work around that restriction by letting select insurers offer the benefit voluntarily, gathering data on cost and outcomes in the process.
The goal was modest but meaningful: create a pathway. Build an evidence base. Eventually push toward broader coverage.
That pathway is now closed — at least for the moment.
Why Did the Administration Cancel It?
No detailed public explanation has been issued. But the decision fits within a broader pattern of rolling back healthcare spending expansions proposed under the previous administration.
Cost is almost certainly a factor. GLP-1 medications remain among the most expensive drugs on the market. Wegovy carries a list price of over $1,300 per month. Extending Medicare coverage to tens of millions of seniors with obesity — without a negotiated price reduction — would represent a massive budget commitment.
There's also a political dimension. Obesity drug coverage remains controversial among fiscal conservatives, who argue that lifestyle interventions should come first. That view doesn't reflect the current clinical evidence, but it continues to influence policy decisions at the federal level.
Who Gets Hurt Most by This Decision?
Seniors living with obesity who do not have a qualifying diagnosis of type 2 diabetes or established cardiovascular disease are the most directly affected.
If you're on Medicare and your doctor wants to prescribe Wegovy or Zepbound solely for weight management, you're almost certainly paying out of pocket — and that cost is prohibitive for most people on fixed incomes.
This disparity already existed before the pilot was proposed. What changed is that a potential solution has been taken off the table, with no replacement announced.
It's also worth noting that obesity in older adults is not a cosmetic concern. It's linked to joint deterioration, sleep apnea, heart disease, type 2 diabetes, and reduced mobility. Treating it has real downstream effects on the broader Medicare budget.
What Coverage Options Still Exist for Seniors?
The situation is frustrating, but it's not entirely without options. Here's where coverage can still apply:
Medicare Part D covers GLP-1s for type 2 diabetes. If you have a diabetes diagnosis, drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide) may be covered under your Part D plan, though formulary placement varies.
Medicare covers Wegovy for cardiovascular risk reduction. Following the SELECT trial, which showed semaglutide reduced major cardiovascular events in people with obesity and existing heart disease, CMS expanded coverage for Wegovy in that specific population. If you have documented cardiovascular disease, this may be your pathway in.
Medicare Advantage plans vary. Some private Medicare Advantage plans have begun covering GLP-1s more broadly. It's worth calling your plan directly to ask what's on your formulary.
Manufacturer savings programs. Novo Nordisk and Eli Lilly both offer patient assistance programs, though these are typically limited to people without insurance rather than those with Medicare.
Talk to your doctor about which of these options applies to your specific situation. There's no one-size-fits-all answer here.
Could This Decision Be Reversed?
Possibly. Federal health policy is not static.
Congressional pressure to expand GLP-1 coverage has been growing from both sides of the aisle. The Treat and Reduce Obesity Act — legislation that would explicitly allow Medicare to cover obesity medications — has been introduced in multiple sessions of Congress, though it has yet to pass.
The clinical data supporting GLP-1s for obesity is strong and continues to accumulate. As long-term outcomes data matures and healthcare economists build a clearer picture of cost savings from reduced hospitalizations and complications, the policy calculus may shift.
The pilot program's cancellation is a setback. It's not necessarily permanent.
No waiting list. No insurance needed.
Frequently Asked Questions
What was the Medicare GLP-1 pilot program that was cancelled?
The pilot was a Biden-era proposal designed to test whether Medicare could cover GLP-1 receptor agonists specifically for obesity treatment in older adults. Under current law, Medicare is prohibited from covering weight loss drugs, though it can cover GLP-1s for type 2 diabetes or cardiovascular risk reduction. The pilot would have let select insurers offer obesity drug coverage voluntarily, building an evidence base for potential broader coverage. The Trump administration dropped the plan without a detailed public explanation.
Why did the Trump administration cancel the Medicare GLP-1 pilot?
No detailed public explanation has been issued. Cost is almost certainly a factor, since GLP-1 medications like Wegovy carry list prices exceeding $1,300 per month, and extending coverage to tens of millions of seniors with obesity would represent an enormous budget commitment without negotiated price reductions. The decision also fits within a broader pattern of rolling back healthcare spending expansions proposed under the previous administration, and reflects ongoing political opposition to obesity drug coverage among fiscal conservatives.
Does Medicare cover any GLP-1 medications for seniors at all?
Yes, in specific circumstances. Medicare Part D covers GLP-1s including Ozempic and Mounjaro for type 2 diabetes management. Following the SELECT trial, CMS expanded Wegovy coverage for people with obesity and documented cardiovascular disease. Some Medicare Advantage plans have also begun covering GLP-1s more broadly on their formularies. What remains uncovered is GLP-1 therapy for obesity alone without a qualifying diabetes or cardiovascular diagnosis.
Who is most affected by the cancellation of the pilot program?
Seniors living with obesity who do not have a qualifying diagnosis of type 2 diabetes or established cardiovascular disease are most directly affected. These patients cannot access GLP-1 coverage through existing Medicare pathways and face out-of-pocket costs that are prohibitive on fixed incomes. Obesity in older adults is not a cosmetic concern but is linked to joint deterioration, sleep apnea, heart disease, and reduced mobility, making treatment medically significant rather than elective.
Could the Medicare GLP-1 pilot program be reinstated or replaced by legislation?
Possibly. The Treat and Reduce Obesity Act, which would explicitly allow Medicare to cover obesity medications, has been introduced in multiple sessions of Congress and has bipartisan support, though it has not yet passed. As long-term outcomes data from GLP-1 trials continues to accumulate and health economists build a clearer picture of downstream cost savings from reduced hospitalizations and complications, the policy calculus may shift. The pilot cancellation is a setback but not necessarily a permanent outcome.
What should Medicare seniors do right now if they need access to GLP-1 medications?
Talk directly with your physician about your eligibility under existing coverage pathways. Ask whether your cardiovascular disease history qualifies you for the Wegovy CMS coverage expansion, whether any existing diagnoses create a Part D pathway, and whether your Medicare Advantage plan covers GLP-1s on its formulary. Do not assume coverage does not exist without checking your specific plan. Manufacturer patient assistance programs from Novo Nordisk and Eli Lilly may also apply in some situations, though these are typically more limited for Medicare beneficiaries than for those without insurance.